Effect of CCK antagonists CR 1409 and CR 1505 on rat pancreatic exocrine secretion in vivo.
The action of cholecystokinin (CCK) antagonists CR 1409 and CR 1505 on pancreatic exocrine secretion stimulated by exogenous and endogenous CCK was studied in vivo in anesthetized rats, and compared with proglumide. Intravenous administration of CR 1409 and CR 1505 in graded doses between 0.04 and 25 mg/kg/h resulted in a dose-dependent inhibition in pancreatic juice volume and amylase output stimulated by intravenous infusion of CCK-8 in a dose of 0.06 microgram/kg/h. CR 1409 is 1,000 times and CR 1505 is 267 times more potent than proglumide, based on the ED50 (effective dose for half-maximal inhibition) for CCK-8-stimulated amylase secretion. Intraduodenal administration of casein in a dose of 400 mg/h caused significant increases in plasma CCK concentration and pancreatic secretion of juice volume and outputs of amylase and trypsin. Both CR 1409 and CR 1505 in a dose of 5 mg/kg/h suppressed the increases in pancreatic juice volume and both amylase and trypsin outputs induced by casein given intraduodenally. These results indicate that CCK antagonists including CR 1409, CR 1505, and proglumide inhibit pancreatic exocrine secretion stimulated by not only exogenous, but also endogenous CCK in rats.
Shiratori
K
K
Department of Medicine and Gastroenterology, Tokyo Women's Medical College, Japan.
Shimizu
K
K
Watanabe
S
S
Takeuchi
T
T
Moriyoshi
Y
Y
D000818:Animals; D002364:Caseins / Q000494:pharmacology; D002766:Cholecystokinin / Q000037:antagonists & inhibitors* / Q000097:blood / Q000494:pharmacology; D008297:Male; D010179:Pancreas / Q000378:metabolism*; D011377:Proglumide / Q000494:pharmacology / Q000031:analogs & derivatives; D051381:Rats; D011919:Rats, Inbred Strains
D002364:Caseins; C053737:loxiglumide; D002766:Cholecystokinin; D011377:Proglumide; C048181:lorglumide